Body-composition coverage on Peptide News Digest tracks the lean-mass / fat-mass tradeoff in GLP-1 and dual-agonist treatment. The trial data has been clearer than the popular framing — GLP-1s and bariatric surgery both produce substantial fat-mass reduction alongside modest reductions in lean mass.
Key reads: a JAMA Network Open study showing semaglutide, tirzepatide, and bariatric surgery all produced fat-mass reduction with concurrent reductions in lean mass over 24 months; the Cell Reports Medicine study showing GLP-1 weight loss does not cause disproportionate muscle loss (relative muscle mass and strength actually improved in mice and the proof-of-concept clinical trial); and ongoing work on myostatin antagonists (Apitegromab, trevogrumab, garetosmab) as muscle-preservation add-ons.
Stories here cover the body-composition data and the muscle-preservation pipeline. See #muscle-loss, #muscle-preservation, and #myostatin.
The Journal of Nutrition published online on June 20, 2026 a review titled 'Avoiding malnutrition in the era of GLP-1 medications: emerging evidence and opportunities for integrated nutrition care.' The review documents that approximately 25% of total weight lost on GLP-1 therapy is lean mass — a substantial proportion depending on the magnitude of weight reduction achieved — and frames disproportionate fat-free mass loss as a metabolic-health and physical-function risk independent of total weight loss. The authors call for GLP-1-specific randomized trials defining optimal protein intake stratified by age, rate of weight loss, and baseline sarcopenia risk; guidance on when supplementation may be necessary; strategies for monitoring micronutrient status; and routine incorporation of body composition assessments (DXA/BIA) and standardized muscle function measures (handgrip strength, chair-rise testing) as co-primary or key secondary endpoints in future GLP-1 RA studies.
Boehringer Ingelheim and Zealand Pharma presented a pre-specified body-composition analysis of SYNCHRONIZE-1 at ADA's Monday session: survodutide produced up to 34% relative reduction in visceral fat and 63.1% reduction in liver fat from baseline at 76 weeks, while limiting lean-mass loss. The company also disclosed SYNCHRONIZE-MASLD results: 6 of 10 patients with MASLD reached liver-fat normalization at 48 weeks. The body-composition story is Boehringer's response to a 16.6% headline weight number that analysts had called less competitive than Lilly's.
A second body-composition substudy from REDEFINE 1 presented May 14 at ECO 2026 broke out the DXA subgroup by treatment arm. At week 68, CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg) produced -23.9% weight reduction in the DXA subgroup, compared with -16.6% on semaglutide 2.4 mg alone, -15.0% on cagrilintide 2.4 mg alone, and -2.8% on placebo. The fat-mass-to-lean-tissue ratios were favorable across all active arms: 66.9% fat-mass contribution on CagriSema, 69.7% on semaglutide, 62.9% on cagrilintide. The cagrilintide monotherapy arm is the first head-to-head body-composition signal for amylin-only therapy at clinically meaningful weight-loss levels — relevant to Zealand and Roche's petrelintide Phase 3 program and the broader amylin-versus-incretin debate.
A prespecified body-composition substudy of REDEFINE 1 presented at ECO 2026 reported that 252 participants on CagriSema 2.4 mg/2.4 mg (semaglutide + cagrilintide) achieved a 35.7% relative reduction in fat mass and a 14.4% reduction in lean soft-tissue mass at week 68 — compared with 5.7% and 4.3% on placebo. The headline 22.7% mean weight reduction in REDEFINE 1 (NEJM publication June 2025) thus broke down with a fat-mass-to-lean-tissue ratio of roughly 2.5:1, a more favorable body-composition profile than the typical 1.5-2:1 ratio reported for GLP-1 monotherapy. The data builds the case for combination amylin-GLP-1 therapy as preferentially fat-selective.
Omada Health published results from a 12-week study of 245 adults with obesity comparing its GLP-1 Care Track behavioral program (151 members) to a control group (94). Omada members lost 1.8x more total weight (6.0% vs 3.3% of starting weight), 2.1x more body fat, and saw increased muscle mass percentage and improved mental health scores. The finding directly addresses sarcopenia concerns highlighted in recent NPR coverage of GLP-1 discontinuation.
A Cell Reports Medicine study presenting four preclinical experiments and a proof-of-concept clinical trial reports that GLP-1 medicines predominantly reduce body fat alongside a small but significant decrease in lean body mass in obese mice and humans. Among lean tissues, loss of liver mass exceeds change in muscle mass, and while absolute muscle mass and strength decrease, relative muscle mass and strength improve — translating into better running performance in mice.
Research in JAMA Network Open shows semaglutide, tirzepatide, and bariatric surgery all produce substantial fat mass reduction but also cause reductions in lean mass over 24 months, highlighting the body composition tradeoff in GLP-1 treatment.